Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma

Journal of Clinical Oncology

Volumn 19, Issue 7, 2001, Pages 1985-1992

  Schwartz, G K ^a   Ilson, D ^a   Saltz, L ^a   O'Reilly, E ^a   Tong, W ^a   Maslak, P ^a   Werner, J ^a   Perkins, P ^a   Stoltz, M ^a   Kelsen, D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL;

ADULT; ADVANCED CANCER; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; FATIGUE; FEMALE; HUMAN; LIVER METASTASIS; MALE; MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIODIAGNOSIS; STOMACH CARCINOMA; TUMOR XENOGRAFT; VEIN THROMBOSIS;

EID: 0035300684     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.7.1985     Document Type: Article

References (23)

1. Cancer statistics, 2000
2. The changing epidemiology of esophageal cancer
3. Adjuvant and neoadjuvant therapy for gastric cancer
4. An anti-inflammatory cum immunomodulatory piperidinylbenzopyranone from drysoxylum bineactariferum: Isolation, structure and total synthesis
5. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
6. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275
7. Alteration of the phosphorylation state or p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells
8. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
9. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
10. DNA fragmentation and apoptosis of lymphoma and prostate cancer cell lines after flavopiridol treatment
11. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
12. Phase I clinical and pharmacokinetic trial of flavopiridol
13. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor in patients with refractory neoplasms
14. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
15. Potentiation of apoptosis by flavopiridol in mitomycin-C treated gastric and breast cancer cells
16. Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V, and 7-AAD cytofluorometric staining methods
17. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
18. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study
19. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endo-thelial growth factor expression in human monocytes
20. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
21. A Phase I trial of I hour infusion of flavopiridoL a novel cyclin dependent kinase inhibitor, in patients with advanced neoplasms
22. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
23. Phase I trial of sequential paclitaxel and the cyclin dependent kinase inhibitor flavopiridol